ARCHIVES

CMS Considering Regulatory Standards for Drug Company Bundling of Products.

This article is from The Cancer Letter archive.

Vol. 32 No. 37 | October 20, 2006

Download PDF Visit The Full Archive

Related Articles

Family History of BRCA Mutation Does Not Equal Increased Risk

October 28, 2011

Mammography Hazard In ACS-NCI Screening Charged

October 17, 1975

Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness

July 26, 2013

Congress Provides 7% Increase For NIH, 6.6% for NCI, In FY98 Appropriation

November 14, 1997

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

April 29, 2011

New Treatments And Quality of Life Study For Ovarian Cancer Described At SGO

March 26, 2004